BRC's Q3 13F: $184.6M Portfolio, 87% Concentrated in Babcock & Wilcox
RILY is trading near its 52-week low of $3.415 (1.3% above the low).
Summary
BRC's Q3 2026 13F shows a $184.6M portfolio with $160.3M — about 87% — in Babcock & Wilcox, the investment behind its $243.0M quarterly loss. The remaining 32 positions are small, with Starling Oncology the largest at $4.6M.
Key Events · Ownership and Investor Activity · RILY
-
Q3 Portfolio Totals $184.6M Across 33 Positions
The 13F for the quarter ended 2026-09-30 reports 33 holdings with a combined value of $184,566,894, all under sole voting authority.
-
Babcock & Wilcox Is 87% of the Book
27,446,522 B&W shares valued at $160,287,688; 160287688/184566894 = 86.8% of the reported portfolio.
-
Long Tail of Small Positions
Starling Oncology (722,381 shares, $4,565,448) is the only other holding above $4M; Sequans ($3,967,895), Vulcan Infrastructure ($3,307,653) and Roman DBDR II ($3,232,546) follow.
-
Concentration Ties Equity Story to B&W
The same B&W position drove the $243.0M net loss to common holders ($6.04 per diluted share) reported in the 2026-11-05 10-Q, leaving little diversification behind the stock.
Analysis · RILY · Finance
Here is the first hard look at what BRC actually holds after a quarter in which Babcock & Wilcox losses drove a $243.0M net loss to common holders ($6.04 per diluted share). The answer is uncomfortable: 27,446,522 B&W shares worth $160,287,688 make up roughly 87% of the $184,566,894 portfolio, so the book is effectively a single-name bet on the very investment that produced the loss. The rest is a long tail of 32 small positions — Starling Oncology at $4.6M is the only other holding above $4M. For a company trading near its 52-week low, this confirms there is no diversified asset base to fall back on; the equity story remains levered to B&W's recovery. Note the 13F values are as-reported at quarter-end and will not reflect subsequent price moves.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RILY was trading at $3.46 on NASDAQ in the Finance sector, with a market capitalization of approximately $138.3M. The 52-week trading range was $3.42 to $11.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.